NCT06566391 2024-08-22
Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma
European Institute of Oncology
Phase 2 Unknown
Clinical Trials
75 trialsNCT06151847 2024-02-28
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
University of Kansas Medical Center
Phase 2 Unknown
NCT05135715 2024-02-20
A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)
RemeGen Co., Ltd.
Phase 2 Unknown
NCT02977052 2023-11-15
OpACIN-neo
The Netherlands Cancer Institute
Phase 2 Unknown
NCT05370807 2023-10-24
RegoMel
Universitair Ziekenhuis Brussel
Phase 2 Unknown
NCT02858921 2023-08-30
Neo Trio
Melanoma Institute Australia
Phase 2 Unknown
NCT03808441 2023-08-25
CAcTUS
The Christie NHS Foundation Trust
Phase 2 Unknown
NCT05907512 2023-06-22
Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma
Fudan University
Phase 2 Unknown
NCT05106023 2023-06-07
To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma
Fudan University
Phase 2 Unknown
NCT05263453 2023-05-31
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
Shanghai Kechow Pharma, Inc.
Phase 2 Unknown
NCT05823246 2023-05-26
Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 2 Unknown
NCT05854589 2023-05-11
Effect of Topical Application of Hypertonic Saline on Melanoma on Its Sizes and Number.
Batroussy, Rafik
Phase 2 Unknown
NCT05827770 2023-04-25
The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma
Fudan University
Phase 2 Unknown
NCT03528408 2023-04-11
Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
Hoosier Cancer Research Network
Phase 2 Unknown
NCT03132675 2023-03-27
Keynote-695
OncoSec Medical Incorporated
Phase 2 Unknown
NCT05767879 2023-03-14
(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma
Leiden University Medical Center
Phase 2 Unknown
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT03913923 2023-02-10
OBERTON
Biocad
Phase 2 Unknown
NCT05664139 2023-02-08
Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma
Fujian Cancer Hospital
Phase 2 Unknown
NCT04633902 2022-12-06
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation
California Pacific Medical Center Research Institute
Phase 2 Unknown
NCT05051865 2022-11-17
To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT05406466 2022-11-10
Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis
Fudan University
Phase 2 Unknown
NCT02036086 2022-10-27
Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Sunnybrook Health Sciences Centre
Phase 2 Unknown
NCT04913025 2022-09-21
REFINE
University College, London
Phase 2 Unknown
NCT03780608 2022-06-15
This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)
Samsung Medical Center
Phase 2 Unknown
NCT05104801 2021-11-04
Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT05097378 2021-10-28
PREMIUM
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Unknown
NCT03925350 2021-10-22
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation
California Pacific Medical Center Research Institute
Phase 2 Unknown
NCT04979585 2021-08-03
Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma
The First Hospital of Jilin University
Phase 2 Unknown
NCT04928365 2021-06-16
Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy
Blokhin's Russian Cancer Research Center
Phase 2 Unknown
NCT04884997 2021-05-13
A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT03313323 2021-04-15
Zirconipi
Amsterdam UMC, location VUmc
Phase 2 Unknown
NCT02501551 2021-04-05
Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy
Yonsei University
Phase 2 Unknown
NCT02617849 2021-02-18
Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma
Jewish General Hospital
Phase 2 Unknown
NCT04749485 2021-02-11
A Study of HX008 for the Treatment of Patients With Malignant Melanoma
Taizhou Hanzhong biomedical co. LTD
Phase 2 Unknown
NCT04593485 2020-12-23
Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract
Fudan University
Phase 2 Unknown
NCT03013101 2020-09-30
Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Unknown
NCT03269565 2020-09-18
MIRACULUM
Biocad
Phase 2 Unknown
NCT03544723 2020-06-09
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Phase 2 Unknown
NCT04397770 2020-05-21
Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT04200040 2020-02-27
A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients
OrienGene Biotechnology Ltd.
Phase 2 Unknown
NCT04250246 2020-01-31
NIBIT-ML1
Italian Network for Tumor Biotherapy Foundation
Phase 2 Unknown
NCT04001725 2019-11-13
OPTIMAL
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT04017897 2019-07-12
The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma
Yonsei University
Phase 2 Unknown
NCT03955354 2019-05-20
PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT03917069 2019-04-17
Nab-PCE vs PC for MM After Failure of Anti-PD-1
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT03190824 2019-04-16
Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma
Syneos Health
Phase 2 Unknown
NCT00604136 2018-09-18
Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy
Hadassah Medical Organization
Phase 2 Unknown
NCT03454919 2018-03-06
Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT03383237 2017-12-27
Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma
Henan Cancer Hospital
Phase 2 Unknown